IP Library Granted Patent US 11,299,748
Granted Patent B2
US 11,299,748 · App. 16/073,343 · Granted Apr 12, 2022

Kit for constructing transposon and use thereof

Inventor: Sareina Chiung-Yuan Wu (Taipei, TW)
C12N15/85C12N9/1241C12Y207/07C12N2800/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,299,748
App. No.
16/073,343
Granted
Apr 12, 2022
Kind
B2
Abstract

A kit for constructing a transposon is provided. The kit comprises five plasmids, each of which consists essentially of a gene cassette linked or not linked to a terminal repeat. The kit is useful in selecting the type of piggyBac that exhibits the least enhancer activity in the host cells.

Claims (25)

1. A method of constructing a transposon capable of introducing an exogenous gene into host cells, comprising,

(1) respectively transfecting the host cells with a control plasmid and a first to a fourth plasmids, wherein,

the control plasmid consists essentially of, a gene cassette, which comprises a promoter of SEQ ID NO: 5 and a reporter gene operably linked to the promoter; and

the first to the fourth plasmids consist essentially of, the gene cassette of the control plasmid and, respectively, a first to a fourth terminal repeats disposed upstream of the gene cassette, wherein the first to the fourth terminal repeats respectively consist of the nucleotide sequences of SEQ ID NOs: 1 to 4;

(2) determining a control expression level of the reporter gene of the control plasmid in the host cells and respective expression levels of the respective reporter genes of the first to the fourth plasmids in the host cells; and

(3) constructing the transposon that consists essentially of, (i) an expression cassette comprising a non-prokaryotic promoter and an exogenous gene operably linked to the non-prokaryotic promoter, (ii) a first selected terminal repeat, which is one of the first to the fourth terminal repeats that elicits an expression level closest to the control expression level, and (iii) a second selected terminal repeat, wherein,

(3a) when the first selected terminal repeat is the first or the third terminal repeat, the first selected terminal repeat is disposed upstream of the expression cassette, and the second selected terminal repeat is the second or the fourth terminal repeat that is disposed downstream of the gene cassette; or

(3b) when the first selected terminal repeat is the second or the fourth terminal repeat, the first selected terminal repeat is disposed downstream of the expression cassette, and the second selected terminal repeat is the first or the third terminal repeat that is disposed upstream of the gene cassette.

2. The method of claim 1 , wherein

in the step (3a), the second selected terminal repeat is the second or the fourth terminal repeat that elicits an expression level closer to the control expression level; or

in the step (3b), the second selected terminal repeat is the first or the third terminal repeat that elicits an expression level closer to the control expression level.

3. The method of claim 1 , wherein

in the step (3a), when the first selected terminal repeat is the first terminal repeat, the second selected terminal repeat is the second terminal repeat; or when the first selected terminal repeat is the third terminal repeat, the second selected terminal repeat is the fourth terminal repeat; or

in the step (3b), when the first selected terminal repeat is the second terminal repeat, the second selected terminal repeat is the first terminal repeat; or when the first selected terminal repeat is the fourth terminal repeat, the second selected terminal repeat is the third terminal repeat.

4. The method of claim 1 , wherein the host cells are mammalian origin or insect origin.

5. The method of claim 4 , wherein the host cells are immune cells selected from the group consisting of, T cells, B cells, natural killer cells, dendritic cells, macrophages, and mast cells.

6. The method of claim 4 , wherein the host cells are stem cells derived from bone marrow, adipose tissue, peripheral blood, umbilical cord blood, or dental pulp.

7. The method of claim 4 , wherein the host cells are epithelial cells.

8. The method of claim 1 , wherein the non-prokaryotic promoter is an inducible promoter.

9. The method of claim 1 , wherein the non-prokaryotic promoter is a constitutive promoter.

10. The method of claim 9 , wherein the non-prokaryotic promoter is cytomegalovirus (CMV) promoter, rous sarcoma virus (RSV) promoter, simian virus (SV40) promoter, mouse mammary tumor virus (MMTV) promoter, phosphoglycerate kinase (PGK) promoter, chicken beta-active promoter, elongation factor 1-alpha (EF1-α) promoter, human H1 promoter, or U6 promoter.

11. A kit comprising,

a control plasmid consisting essentially of, a gene cassette, which comprises a promoter of SEQ ID NO: 5 and a reporter gene operably linked to the promoter; and

a first to a fourth plasmids consisting essentially of, the gene cassette and, respectively, a first to a fourth terminal repeats disposed upstream of the gene cassette, wherein the first to the fourth terminal repeats respectively consist of the nucleotide sequences of SEQ ID NOs: 1 to 4.

12. The kit of claim 11 , wherein the reporter gene encodes a fluorescent protein or a luminescent protein.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2026
From: GENOMEFRONTIER THERAPEUTICS TW CO., LTD.
To: GENOMEFRONTIER THERAPEUTICS, CORP.
Reel/Frame 074636/0626 →
CHANGE OF NAME Recorded Sep 26, 2024
From: GENOMEFRONTIER THERAPEUTICS, INC.
To: GENOMEFRONTIER THERAPEUTICS TW CO., LTD.
Reel/Frame 069066/0094 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2020
From: GENOMEFRONTIER THERAPEUTICS, INC.
To: GENOMEFRONTIER THERAPEUTICS, INC.
Reel/Frame 054735/0244 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2018
From: WU, SAREINA CHIUNG-YUAN
To: GENOMEFRONTIER THERAPEUTICS, INC.
Reel/Frame 046609/0574 →
Continuity (1)
Related Publication 20190040414A1 · Feb 7, 2019